Related references
Note: Only part of the references are listed.Innovative Clinical Trials: The LUNG-MAP Study
C. E. Steuer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Are outcome-adaptive allocation trials ethical? Commentary
J. Jack Lee
CLINICAL TRIALS (2015)
Commentary on Hey and Kimmelman
Edward L Korn et al.
Clinical Trials (2015)
Are outcome-adaptive allocation trials ethical? Commentary
Donald A. Berry
CLINICAL TRIALS (2015)
Are outcome-adaptive allocation trials ethical?
Spencer Phillips Hey et al.
CLINICAL TRIALS (2015)
The Platform Trial An Efficient Strategy for Evaluating Multiple Treatments
Scott M. Berry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Fusing Randomized Trials With Big Data The Key to Self-learning Health Care Systems?
Derek C. Angus
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research
Donald A. Berry
MOLECULAR ONCOLOGY (2015)
The utility of Bayesian predictive probabilities for interim monitoring of clinical trials
Benjamin R. Saville et al.
CLINICAL TRIALS (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials
Scott M. Berry et al.
CLINICAL TRIALS (2013)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs
Laura J. Esserman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The FDA critical path initiative and its influence on new drug development
Janet Woodcock et al.
ANNUAL REVIEW OF MEDICINE (2008)
Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine
Xian Zhou et al.
CLINICAL TRIALS (2008)
Share Paper
